ID   MARK3_HUMAN             Reviewed;         753 AA.
AC   P27448; A0A0A0MQR8; A0A0A0MST9; A0A0A0MT23; O60219; Q86TT8; Q8TB41; Q8WX83;
AC   Q96RG1; Q9UMY9; Q9UN34;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 5.
DT   12-OCT-2022, entry version 215.
DE   RecName: Full=MAP/microtubule affinity-regulating kinase 3;
DE            EC=2.7.11.1;
DE   AltName: Full=C-TAK1;
DE            Short=cTAK1;
DE   AltName: Full=Cdc25C-associated protein kinase 1;
DE   AltName: Full=ELKL motif kinase 2;
DE            Short=EMK-2;
DE   AltName: Full=Protein kinase STK10;
DE   AltName: Full=Ser/Thr protein kinase PAR-1;
DE            Short=Par-1a;
DE   AltName: Full=Serine/threonine-protein kinase p78;
GN   Name=MARK3; Synonyms=CTAK1, EMK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANT GLY-443.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9543386;
RA   Peng C.Y., Graves P.R., Ogg S., Thoma R.S., Byrnes M.J. III, Wu Z.,
RA   Stephenson M.T., Piwnica-Worms H.;
RT   "C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and
RT   promotes 14-3-3 protein binding.";
RL   Cell Growth Differ. 9:197-208(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT GLY-443.
RC   TISSUE=Monocyte;
RA   Waggoner S.N., Stephen R., Farrar W.L., Howard O.M.Z.;
RT   "Human serine/threonine protein kinase cTAK1/Kp78/Mark3: Identification of
RT   a novel splice variant and a larger 5'UTR.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=11433294; DOI=10.1038/35083016;
RA   Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J.,
RA   Williams L.T.;
RT   "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt
RT   signalling.";
RL   Nat. Cell Biol. 3:628-636(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Drewes G.;
RT   "Characterization of an alternatively spliced form of MARK3 from human
RT   brain.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Pancreas;
RA   Maheshwari K.K., Som S., Parsa I.;
RL   Submitted (JAN-1992) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7), AND VARIANT PHE-410.
RC   TISSUE=Neuroblastoma;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 300-752 (ISOFORM 6).
RC   TISSUE=Urinary bladder;
RA   Reynolds C.H., Patel U.A., Anderton B.H.;
RT   "Homo sapiens mRNA partial sequence for a protein kinase, STK10, similar to
RT   p78/C-TAK1.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   FUNCTION, AND INTERACTION WITH PKP2; KSR1 AND CDC25C.
RX   PubMed=12941695; DOI=10.1093/emboj/cdg426;
RA   Mueller J., Ritt D.A., Copeland T.D., Morrison D.K.;
RT   "Functional analysis of C-TAK1 substrate binding and identification of PKP2
RT   as a new C-TAK1 substrate.";
RL   EMBO J. 22:4431-4442(2003).
RN   [12]
RP   PHOSPHORYLATION AT THR-564.
RX   PubMed=15084291; DOI=10.1016/j.cub.2004.04.007;
RA   Hurov J.B., Watkins J.L., Piwnica-Worms H.;
RT   "Atypical PKC phosphorylates PAR-1 kinases to regulate localization and
RT   activity.";
RL   Curr. Biol. 14:736-741(2004).
RN   [13]
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT THR-211, AND MUTAGENESIS OF
RP   THR-211.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J.,
RA   Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily,
RT   including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [14]
RP   FUNCTION.
RX   PubMed=16980613; DOI=10.1128/mcb.00231-06;
RA   Dequiedt F., Martin M., Von Blume J., Vertommen D., Lecomte E., Mari N.,
RA   Heinen M.F., Bachmann M., Twizere J.C., Huang M.C., Rider M.H.,
RA   Piwnica-Worms H., Seufferlein T., Kettmann R.;
RT   "New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and
RT   activity of class IIa histone deacetylases.";
RL   Mol. Cell. Biol. 26:7086-7102(2006).
RN   [15]
RP   INTERACTION WITH YWHAB; YWHAG; YWHAQ AND YWHAZ.
RX   PubMed=16959763; DOI=10.1074/mcp.m600147-mcp200;
RA   Angrand P.O., Segura I., Voelkel P., Ghidelli S., Terry R., Brajenovic M.,
RA   Vintersten K., Klein R., Superti-Furga G., Drewes G., Kuster B.,
RA   Bouwmeester T., Acker-Palmer A.;
RT   "Transgenic mouse proteomics identifies new 14-3-3-associated proteins
RT   involved in cytoskeletal rearrangements and cell signaling.";
RL   Mol. Cell. Proteomics 5:2211-2227(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-549, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-383; SER-400; SER-469;
RP   THR-549; SER-598 AND SER-643, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT
RP   SER-384 (ISOFORM 5), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-407
RP   (ISOFORM 6), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-42; SER-383; SER-469 AND
RP   SER-643, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21145462; DOI=10.1016/j.cell.2010.11.028;
RA   Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D.,
RA   Janmey P.A., Lemmon M.A.;
RT   "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by
RT   binding acidic phospholipids.";
RL   Cell 143:966-977(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-469, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-376; SER-380; SER-419;
RP   SER-469; SER-540; THR-549; SER-583 AND SER-601, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION.
RX   PubMed=23666762; DOI=10.1007/s12017-013-8232-3;
RA   Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G.,
RA   Landegren U., Sunnemark D., Kamali-Moghaddam M.;
RT   "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in
RT   Alzheimer's disease.";
RL   NeuroMolecular Med. 15:458-469(2013).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH STK3; STK4 AND DLG5.
RX   PubMed=28087714; DOI=10.1101/gad.284539.116;
RA   Kwan J., Sczaniecka A., Arash E.H., Nguyen L., Chen C.C., Ratkovic S.,
RA   Klezovitch O., Attisano L., McNeill H., Emili A., Vasioukhin V.;
RT   "DLG5 connects cell polarity and Hippo signaling protein networks by
RT   linking PAR-1 with MST1/2.";
RL   Genes Dev. 30:2696-2709(2016).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-429 AND GLY-443.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [29]
RP   VARIANT VIPB GLY-570, AND INVOLVEMENT IN VIPB.
RX   PubMed=29771303; DOI=10.1093/hmg/ddy180;
RA   Ansar M., Chung H., Waryah Y.M., Makrythanasis P., Falconnet E., Rao A.R.,
RA   Guipponi M., Narsani A.K., Fingerhut R., Santoni F.A., Ranza E.,
RA   Waryah A.M., Bellen H.J., Antonarakis S.E.;
RT   "Visual impairment and progressive phthisis bulbi caused by recessive
RT   pathogenic variant in MARK3.";
RL   Hum. Mol. Genet. 27:2703-2711(2018).
CC   -!- FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved
CC       in the specific phosphorylation of microtubule-associated proteins for
CC       MAP2 and MAP4. Phosphorylates the microtubule-associated protein
CC       MAPT/TAU (PubMed:23666762). Phosphorylates CDC25C on 'Ser-216'
CC       (PubMed:12941695). Regulates localization and activity of some histone
CC       deacetylases by mediating phosphorylation of HDAC7, promoting
CC       subsequent interaction between HDAC7 and 14-3-3 and export from the
CC       nucleus (PubMed:16980613). Negatively regulates the Hippo signaling
CC       pathway and antagonizes the phosphorylation of LATS1. Cooperates with
CC       DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1
CC       (PubMed:28087714). Phosphorylates PKP2 and KSR1 (PubMed:12941695).
CC       {ECO:0000269|PubMed:12941695, ECO:0000269|PubMed:16980613,
CC       ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:28087714}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-211. Inhibited
CC       by phosphorylation on Thr-564. {ECO:0000269|PubMed:14976552}.
CC   -!- SUBUNIT: Interacts with MAPT/TAU (PubMed:23666762). Interacts with DLG5
CC       (via coiled-coil domain). Interacts with STK3/MST2 and STK4/MST1 in the
CC       presence of DLG5 (PubMed:28087714). Interacts with YWHAB, YWHAG, YWHAQ
CC       and YWHAZ (PubMed:16959763). Interacts with PKP2 (via N-terminus)
CC       (PubMed:12941695). Interacts with CDC25C (PubMed:12941695). Interacts
CC       with KSR1 (PubMed:12941695). {ECO:0000269|PubMed:12941695,
CC       ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:23666762,
CC       ECO:0000269|PubMed:28087714}.
CC   -!- INTERACTION:
CC       P27448; Q8WXK3: ASB13; NbExp=2; IntAct=EBI-707595, EBI-707573;
CC       P27448; P31947: SFN; NbExp=2; IntAct=EBI-707595, EBI-476295;
CC       P27448; Q15560: TCEA2; NbExp=2; IntAct=EBI-707595, EBI-710310;
CC       P27448; P31946: YWHAB; NbExp=5; IntAct=EBI-707595, EBI-359815;
CC       P27448; P61981: YWHAG; NbExp=4; IntAct=EBI-707595, EBI-359832;
CC       P27448; Q04917: YWHAH; NbExp=6; IntAct=EBI-707595, EBI-306940;
CC       P27448; P63104: YWHAZ; NbExp=12; IntAct=EBI-707595, EBI-347088;
CC       P27448; Q6S8E0: ORF9b; Xeno; NbExp=2; IntAct=EBI-707595, EBI-25489144;
CC       P27448; Q8BHN0: Ppm1l; Xeno; NbExp=3; IntAct=EBI-707595, EBI-7970002;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21145462};
CC       Peripheral membrane protein {ECO:0000269|PubMed:21145462}. Cell
CC       projection, dendrite {ECO:0000269|PubMed:23666762}. Cytoplasm
CC       {ECO:0000269|PubMed:23666762}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=P27448-5; Sequence=Displayed;
CC       Name=2; Synonyms=CTAK75a;
CC         IsoId=P27448-2; Sequence=VSP_041582, VSP_004944;
CC       Name=3;
CC         IsoId=P27448-3; Sequence=VSP_004944;
CC       Name=4;
CC         IsoId=P27448-4; Sequence=VSP_004945;
CC       Name=5; Synonyms=p58;
CC         IsoId=P27448-6; Sequence=VSP_004943, VSP_004944;
CC       Name=6;
CC         IsoId=P27448-7; Sequence=VSP_041582, VSP_004943;
CC       Name=7;
CC         IsoId=P27448-8; Sequence=VSP_043197, VSP_043198;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylated at Thr-211 by STK11/LKB1 in complex with STE20-
CC       related adapter-alpha (STRADA) pseudo kinase and CAB39. Phosphorylation
CC       at Thr-564 by PRKCZ/aPKC inhibits the kinase activity.
CC       {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15084291}.
CC   -!- DISEASE: Visual impairment and progressive phthisis bulbi (VIPB)
CC       [MIM:618283]: An autosomal recessive, progressive disease characterized
CC       by poor vision at birth and development of bilateral phthisis bulbi by
CC       adulthood. {ECO:0000269|PubMed:29771303}. Note=The disease may be
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U64205; AAC15093.1; -; mRNA.
DR   EMBL; AF159295; AAD48007.1; -; mRNA.
DR   EMBL; AF387637; AAK82367.1; -; mRNA.
DR   EMBL; AF465413; AAL69982.1; -; mRNA.
DR   EMBL; M80359; AAA59991.1; -; mRNA.
DR   EMBL; BX161395; CAD61882.1; -; mRNA.
DR   EMBL; AL133367; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF456011; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471061; EAW81813.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW81815.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW81817.1; -; Genomic_DNA.
DR   EMBL; BC024773; AAH24773.1; -; mRNA.
DR   EMBL; AF170723; AAD51631.1; -; mRNA.
DR   CCDS; CCDS41993.1; -. [P27448-3]
DR   CCDS; CCDS45165.1; -. [P27448-5]
DR   CCDS; CCDS45166.1; -. [P27448-4]
DR   CCDS; CCDS45167.1; -. [P27448-8]
DR   CCDS; CCDS55947.1; -. [P27448-6]
DR   PIR; S27966; S27966.
DR   RefSeq; NP_001122390.2; NM_001128918.2. [P27448-5]
DR   RefSeq; NP_001122391.2; NM_001128919.2. [P27448-4]
DR   RefSeq; NP_001122392.2; NM_001128920.2. [P27448-6]
DR   RefSeq; NP_001122393.2; NM_001128921.2. [P27448-8]
DR   RefSeq; NP_002367.5; NM_002376.6. [P27448-3]
DR   PDB; 2QNJ; X-ray; 2.70 A; A/B=48-370.
DR   PDB; 3FE3; X-ray; 1.90 A; A/B=41-367.
DR   PDB; 7P1L; X-ray; 1.95 A; A/B=48-366.
DR   PDBsum; 2QNJ; -.
DR   PDBsum; 3FE3; -.
DR   PDBsum; 7P1L; -.
DR   AlphaFoldDB; P27448; -.
DR   BMRB; P27448; -.
DR   SMR; P27448; -.
DR   BioGRID; 110310; 193.
DR   DIP; DIP-34637N; -.
DR   IntAct; P27448; 115.
DR   MINT; P27448; -.
DR   STRING; 9606.ENSP00000411397; -.
DR   BindingDB; P27448; -.
DR   ChEMBL; CHEMBL5600; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P27448; -.
DR   GuidetoPHARMACOLOGY; 2099; -.
DR   GlyGen; P27448; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P27448; -.
DR   MetOSite; P27448; -.
DR   PhosphoSitePlus; P27448; -.
DR   BioMuta; MARK3; -.
DR   DMDM; 341941142; -.
DR   EPD; P27448; -.
DR   jPOST; P27448; -.
DR   MassIVE; P27448; -.
DR   MaxQB; P27448; -.
DR   PaxDb; P27448; -.
DR   PeptideAtlas; P27448; -.
DR   PRIDE; P27448; -.
DR   ProteomicsDB; 54386; -. [P27448-5]
DR   ProteomicsDB; 54387; -. [P27448-2]
DR   ProteomicsDB; 54388; -. [P27448-3]
DR   ProteomicsDB; 54389; -. [P27448-4]
DR   ProteomicsDB; 54390; -. [P27448-6]
DR   ProteomicsDB; 54391; -. [P27448-7]
DR   ProteomicsDB; 54392; -. [P27448-8]
DR   Antibodypedia; 6515; 496 antibodies from 36 providers.
DR   DNASU; 4140; -.
DR   Ensembl; ENST00000216288.11; ENSP00000216288.7; ENSG00000075413.19. [P27448-6]
DR   Ensembl; ENST00000303622.13; ENSP00000303698.9; ENSG00000075413.19. [P27448-3]
DR   Ensembl; ENST00000416682.6; ENSP00000408092.2; ENSG00000075413.19. [P27448-2]
DR   Ensembl; ENST00000429436.7; ENSP00000411397.2; ENSG00000075413.19. [P27448-5]
DR   Ensembl; ENST00000440884.7; ENSP00000402104.3; ENSG00000075413.19. [P27448-8]
DR   Ensembl; ENST00000553942.5; ENSP00000450772.1; ENSG00000075413.19. [P27448-4]
DR   GeneID; 4140; -.
DR   KEGG; hsa:4140; -.
DR   MANE-Select; ENST00000429436.7; ENSP00000411397.2; NM_001128918.3; NP_001122390.2.
DR   UCSC; uc001ymw.5; human. [P27448-5]
DR   UCSC; uc001ymy.5; human.
DR   UCSC; uc001ymz.5; human.
DR   UCSC; uc001yna.5; human.
DR   CTD; 4140; -.
DR   DisGeNET; 4140; -.
DR   GeneCards; MARK3; -.
DR   HGNC; HGNC:6897; MARK3.
DR   HPA; ENSG00000075413; Low tissue specificity.
DR   MalaCards; MARK3; -.
DR   MIM; 602678; gene.
DR   MIM; 618283; phenotype.
DR   neXtProt; NX_P27448; -.
DR   OpenTargets; ENSG00000075413; -.
DR   PharmGKB; PA30640; -.
DR   VEuPathDB; HostDB:ENSG00000075413; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   GeneTree; ENSGT00940000154862; -.
DR   InParanoid; P27448; -.
DR   OMA; AKFRQGC; -.
DR   TreeFam; TF315213; -.
DR   PathwayCommons; P27448; -.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; P27448; -.
DR   SIGNOR; P27448; -.
DR   BioGRID-ORCS; 4140; 28 hits in 1124 CRISPR screens.
DR   ChiTaRS; MARK3; human.
DR   EvolutionaryTrace; P27448; -.
DR   GeneWiki; MARK3; -.
DR   GenomeRNAi; 4140; -.
DR   Pharos; P27448; Tchem.
DR   PRO; PR:P27448; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P27448; protein.
DR   Bgee; ENSG00000075413; Expressed in cerebellar hemisphere and 203 other tissues.
DR   ExpressionAtlas; P27448; baseline and differential.
DR   Genevisible; P27448; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0035331; P:negative regulation of hippo signaling; IDA:UniProtKB.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR001772; KA1_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033628; MARK3.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015940; UBA.
DR   PANTHER; PTHR24346:SF1; PTHR24346:SF1; 2.
DR   Pfam; PF02149; KA1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50032; KA1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Cell projection; Cytoplasm; Disease variant; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..753
FT                   /note="MAP/microtubule affinity-regulating kinase 3"
FT                   /id="PRO_0000086304"
FT   DOMAIN          56..307
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          326..365
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   DOMAIN          704..753
FT                   /note="KA1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00565"
FT   REGION          1..36
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          370..600
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          632..655
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        14..28
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        370..418
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        488..548
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        578..600
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        178
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         62..70
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         85
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         211
FT                   /note="Phosphothreonine; by LKB1"
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03141"
FT   MOD_RES         374
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03141"
FT   MOD_RES         376
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         400
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         469
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         540
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         543
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03141"
FT   MOD_RES         549
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   MOD_RES         564
FT                   /note="Phosphothreonine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         583
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         598
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         601
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         643
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         161
FT                   /note="Q -> QGCQAGQTIKVQVSFDLLSLMFTF (in isoform 2 and
FT                   isoform 6)"
FT                   /evidence="ECO:0000303|Ref.2"
FT                   /id="VSP_041582"
FT   VAR_SEQ         179..257
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_043197"
FT   VAR_SEQ         371..386
FT                   /note="Missing (in isoform 5 and isoform 6)"
FT                   /evidence="ECO:0000303|Ref.10, ECO:0000303|Ref.5"
FT                   /id="VSP_004943"
FT   VAR_SEQ         615..638
FT                   /note="Missing (in isoform 2, isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9543386, ECO:0000303|Ref.2,
FT                   ECO:0000303|Ref.5"
FT                   /id="VSP_004944"
FT   VAR_SEQ         615..623
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11433294"
FT                   /id="VSP_004945"
FT   VAR_SEQ         624..638
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_043198"
FT   VARIANT         410
FT                   /note="S -> F (in dbSNP:rs10137161)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_080189"
FT   VARIANT         429
FT                   /note="V -> A"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040765"
FT   VARIANT         443
FT                   /note="S -> G (in dbSNP:rs56305318)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9543386, ECO:0000269|Ref.2"
FT                   /id="VAR_046763"
FT   VARIANT         570
FT                   /note="R -> G (in VIPB; dbSNP:rs376395495)"
FT                   /evidence="ECO:0000269|PubMed:29771303"
FT                   /id="VAR_080778"
FT   MUTAGEN         211
FT                   /note="T->A: Prevents phosphorylation and activation by
FT                   STK11/LKB1 complex."
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   CONFLICT        125
FT                   /note="E -> Q (in Ref. 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        139
FT                   /note="E -> K (in Ref. 4; AAL69982 and 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        149
FT                   /note="R -> K (in Ref. 2; AAD48007)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        425
FT                   /note="A -> G (in Ref. 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        456
FT                   /note="S -> T (in Ref. 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        516
FT                   /note="A -> D (in Ref. 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        603
FT                   /note="N -> T (in Ref. 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        645
FT                   /note="E -> K (in Ref. 5; AAA59991)"
FT                   /evidence="ECO:0000305"
FT   STRAND          56..64
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          66..75
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   TURN            76..78
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          81..88
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           89..91
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           94..109
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          118..123
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          125..132
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           140..147
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           152..171
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           181..183
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          184..186
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          192..194
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           201..203
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   STRAND          213..215
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           216..218
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           221..225
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           232..248
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           258..267
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           278..287
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   TURN            292..294
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           298..301
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   TURN            305..310
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           329..337
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           342..350
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   HELIX           356..364
FT                   /evidence="ECO:0007829|PDB:3FE3"
FT   MOD_RES         P27448-6:384
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         P27448-7:407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
SQ   SEQUENCE   753 AA;  84429 MW;  B50B3C145E896B0B CRC64;
     MSTRTPLPTV NERDTENHTS HGDGRQEVTS RTSRSGARCR NSIASCADEQ PHIGNYRLLK
     TIGKGNFAKV KLARHILTGR EVAIKIIDKT QLNPTSLQKL FREVRIMKIL NHPNIVKLFE
     VIETEKTLYL IMEYASGGEV FDYLVAHGRM KEKEARSKFR QIVSAVQYCH QKRIVHRDLK
     AENLLLDADM NIKIADFGFS NEFTVGGKLD TFCGSPPYAA PELFQGKKYD GPEVDVWSLG
     VILYTLVSGS LPFDGQNLKE LRERVLRGKY RIPFYMSTDC ENLLKRFLVL NPIKRGTLEQ
     IMKDRWINAG HEEDELKPFV EPELDISDQK RIDIMVGMGY SQEEIQESLS KMKYDEITAT
     YLLLGRKSSE LDASDSSSSS NLSLAKVRPS SDLNNSTGQS PHHKVQRSVS SSQKQRRYSD
     HAGPAIPSVV AYPKRSQTST ADSDLKEDGI SSRKSSGSAV GGKGIAPASP MLGNASNPNK
     ADIPERKKSS TVPSSNTASG GMTRRNTYVC SERTTADRHS VIQNGKENST IPDQRTPVAS
     THSISSAATP DRIRFPRGTA SRSTFHGQPR ERRTATYNGP PASPSLSHEA TPLSQTRSRG
     STNLFSKLTS KLTRRNMSFR FIKRLPTEYE RNGRYEGSSR NVSAEQKDEN KEAKPRSLRF
     TWSMKTTSSM DPGDMMREIR KVLDANNCDY EQRERFLLFC VHGDGHAENL VQWEMEVCKL
     PRLSLNGVRF KRISGTSIAF KNIASKIANE LKL
//
